%0 Journal Article
%T Montelukast and Coronavirus Disease 2019: A Scoping Review.
%A Sharifinejad N
%A Sharafian S
%A Salekmoghadam S
%A Tavakol M
%A Qorbani M
%J Iran J Allergy Asthma Immunol
%V 20
%N 4
%D Aug 2021 7
%M 34418892
%F 1.57
%X Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.